Design, synthesis and in vitro cytotoxicity of novel dinuclear platinum(II) complexes

A potent aminonaphthalimide platinum(IV) complex with effective antitumor activities in vitro and in vivo displaying dual DNA damage effects on tumor cells

A new aminonaphthalimide platinum(IV) complex was developed by incorporating aminonaphthalimide, a DNA intercalator, into the platinum(IV) system. This complex displayed potent antitumor activities against all tested tumor cell lines in vitro and showed great potential in overcoming drug resistance of cisplatin. Moreover, it remarkably inhibited the growth of CT26 xenografts in BALB/c mice without severe side effects in vivo. Then, the compound exhibited a dual DNA damage antitumor mechanism that it could interact with DNA in tetravalent form via the naphthalimide group to cause DNA lesion, and the further liberation of platinum(II) complex after reduction would induce remarkable secondary damage to DNA. Meanwhile, it caused cell apoptosis through an intrinsic apoptosis pathway by up-regulating the expression of caspase 3 and caspase 9.

Palladium-modified functionalized cyclodextrin as an efficient and recyclable catalyst for reduction of nitroarenes

A kind of palladium-modified functionalized cyclodextrin catalytic system was synthesized and characterized. It showed high activity in the reduction of nitroarenes with the absence of sodium borohydride in water at room temperature.

Synthesis, cytotoxicity, induction of apoptosis, and interaction with DNA of dinuclear platinum(II) complexes

Six dicarboxylato-bridged dinuclear platinum(II) complexes S1-S6, with a newly designed chiral ligand, 2-{[(1R,2R)-2-aminocyclohexyl]amino}propanoic acid (HL), were prepared and spectrally characterized. The in vitro cytotoxicity of all resulting platinum(II) complexes was evaluated against human HCT-116, MCF-7, and HepG-2 tumor cell lines. The results show that all compounds exhibit positive biological activity toward HCT-116 and MCF-7 cell lines, of which complexes S3, S4, and S5, with succinate and its derivatives as bridges, showing better activity than the positive controls. Moreover, double-dyeing flow cytometric resection experiments indicate that the target compounds inhibit tumor cell growth by inducing apoptosis; gel electrophoresis experiments demonstrate the compounds' ability to prompt pET22b plasmid DNA degradation in almost the same way as oxaliplatin.